The Gift of Time for Trauma Surgeons

Minimally Invasive Targeted Hemorrhage Control

The Problem

Trauma surgeons are placed in an untenable position trying to save patients as they hemorrhage but often not having the time required to access the injured site before the patient exsanguinates.

The Market

The hemorrhage treatment market is upwards of $60 Billion USD. EndoShunt’s beachhead market is around $366 Million USD (Based on initial indications of use in trauma field).

The Solution

EndoShunt effectively controls hemorrhage from an injury while maintaining blood flow to the rest of the body, providing trauma surgeons with the time they need to perform definitive repairs.

welcome to EndoShunt

EndoShunt is Nearing Market Readiness

EndoShunt iterative development has yielded fully functional manufactured prototypes with proven efficacy at preventing hemorrhage in benchtop and in vivo simulated traumatic vascular injury studies.

EndoShunt’s regulatory strategy has been built based on the expertise of Health Policy Associated and experts involved in the intended predicate’s FDA clearance. EndoShunt will begin their pursuit of 510(k) clearance following a Q-sub meeting in 2023.

Why EndoShunt

EndoShunt is the solution

We provide trauma surgeons with a way to rapidly gain targeted
control of abdominal hemorrhage.

Development

EndoShunt’s iterative development has produced fully functional manufactured prototypes capable of stopping hemorrhage in vitro and in vivo.

Market Validation

EndoShunt led our cohort through the NSF ICorps program to kick off our founding, completing 300+ interviews of surgeons, value analysis committee members…

Intellectual Property

EndoShunt’s patent portfolio includes the non-provisional utility patent US-20220305241-A1, along with provisional applications US17656,390, and US63/166,133. The company holds all rights to these patents, safeguarding its pioneering endovascular shunt technology for critical blood vessel conditions.

Differentiation

EndoShunt Has a Strong Clinical Precedent

EndoShunt is similar in many ways to permanent stent grafts, widely available for the last few decades, with several key features that allow it to be used by trauma surgeons, rapidly, to prevent patient death from blood loss. These differentiating factors include guidewire free deployment, temporary placement, and length adjustability.

EndoShunt’s, EndoTip™ allows surgeons to deploy EndoShunt without a guidewire, naturally directing the catheter towards the major blood vessels, and preventing the catheter from passing through lacerations to the artery or vein. The EndoShunt device is designed to be as easily removed from the patient as it is to deploy within the patient, in just 30 seconds, with expected deployment lasting no more than two hours. This is a major advantage over permanent stent grafts as it prevents the surgeon from needing to leave a life altering medical device in the trauma patient. Once EndoShunt is deployed it is capable of being rapidly adjusted in size using EndoShunt’s intuitive handle. This allows trauma surgeons to deploy EndoShunt without worrying about immediate precision, and following deployment, adjust the position or length of the shunt too target the control of blood flow.

The patient is first priority in our passion

Annual Traumatic Abdominal Hemorrhage

Annual EndoShunt Indications in Trauma

Annual EndoShunt’s Lives Saved

$ 0 M

EndoShunt’s Trauma Market

Path to Profit

Class II FDA 510(k) Clearance, Pilot Launch, Expansion.

EndoShunt expects to receive FDA clearance in the next 18 months, following which EndoShunt will begin a targeted launch in seven hospitals that EndoShunt has already confirmed support from. During the first year EndoShunt will focus on gathering data and an understanding of how surgeons use the device, and factors such as training required for nursing staff and anesthesiology teams. Following the targeted launch, EndoShunt will begin its expansion phase. During expansion, EndoShunt will hire sales teams in series, with one sales rep covering average of 10 medical centers. Each medical center is expected to have roughly 27 use cases of EndoShunt annually, with EndoShunt at a price point of $6000 a unit.

Funding

EndoShunt has raised $381,000 in funding and in-kind services.

EndoShunt is raising another $2M to achieve FDA 510(k) clearance. This investment will ensure EndoShunt’s achieved design freeze, supply chain qualifications, FDA clearance, and piloted launch production.

Our Team

Always Here For You & Them

Michael Finn-Henry

(Michael@endoshunt.com) is a Mechanical Engineer with published research at MIT and Vanderbilt in assistive robotics and mechatronic solutions, as well as…

Jeremy Levin, MD

(Jeremy@endoshunt.com) is a dual certified attending general, & trauma surgeon, with focused research on trauma devices.

Milad Behbahaninia, MD

(Milad@endoshunt.com) is a dual certified attending general, & trauma surgeon, with a background in biomedical engineering.

Tyler Zanon

(Tyler@endoshunt.com) is a specialist in new medical product development with over a decade of experience at MedLine and AbvVie.

news & Article

our latest news

User Interface Design Grant

We are excited to have won a grant earlier this year with

EndoShunt Wins NSF I-Corps Grant

The NSF I-Corps Grant is one of the most prestigious customer discovery

EndoShunt Begins Conducting I-Corps Interviews

Trauma Community, EndoShunt is looking for people in the trauma and critical

Contact

Compassion Is At The Heart Of Our Care

our email

info@endoshunt.com

our number

+1 (781) 864-8480

fill the form

get in touch

Address

Our Offices

Chicago

965 West Chicago Ave, Chicago, IL 60642

Chicago

Nashville

2100 West End Ave Suite 1300, Nashville, TN 37203

Nashville

Delaware

704 N. King Street Suite 500, P. O. Box 1031, Wilmington DE 19899

Delaware

The information on this website is for general informational purposes only. EndoShunt does not make marketing claims or assertions about device capabilities, and device’s regulatory status is subject to change and has not been evaluated by the FDA. Consult healthcare professionals for medical advice.